Drug Profile

DB OTO

Alternative Names: DB XX2; DB-OTO

Latest Information Update: 06 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Decibel Therapeutics
Class Gene therapies
Mechanism of Action Gene transference; OTOF protein expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Sensorineural hearing loss
New Molecular Entity No

Highest Development Phases

Phase I/II Sensorineural hearing loss

Most Recent Events

25 Feb 2025 DB OTO receives Fast Track designation for Sensorineural hearing loss [Otic,Injection] (In adolescents, In children, In infants) in USA
24 Feb 2025 Adverse events and efficacy data from a phase I/II CHORD trial in Hearing loss released by Regeneron Pharmaceuticals
08 May 2024 Adverse events and efficacy data from a phase I/II CHORD trial in Hearing loss released by Regeneron Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com